Clinical trial
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or…
NCT00017602 · Genta Incorporated, Industry · Completed
Key facts
| NCT number | NCT00017602 |
|---|---|
| Title | Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | Randomized Phase III Study of Dexamethasone With or Without Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Genta Incorporated, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, dexamethasone |
| Start date | Dec 1, 2000 |
| Completion | Apr 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: